Neil M. Iyengar, MD | Authors

January 31, 2023

Closing out their review of treatment strategies for HR+ metastatic breast cancer, a panel of experts highlights ongoing investigations and future directions in care.

January 31, 2023

Expert panelists consider the appropriate use of PARP and immune checkpoint inhibitors, respectively, in the setting of HR+ metastatic breast cancer.

January 24, 2023

A brief review of Trop-2 directed therapy and its role in the HR+ metastatic breast cancer treatment landscape.

January 24, 2023

Centering discussion on HER2-targeted trastuzumab deruxtecan, experts reflect on the presence of HER2-low metastatic breast cancer and optimal treatment strategies.

January 17, 2023

After briefly addressing resistance to endocrine therapy, expert panelists broadly review novel treatment modalities in the setting of HR+ metastatic breast cancer.

January 17, 2023

Expert perspectives review a case of relapsed HR+ metastatic breast cancer and consider treatment options available in the second line and beyond.

January 10, 2023

Highlights from key clinical data informing the selection of targeted therapy in particular subsets of patients with HR+ breast cancer.

January 10, 2023

Comprehensive insight to the selection of CDK4/6 inhibitors as first-line therapy for patients with metastatic HR+ breast cancer, followed by a brief review of available endocrine partners.

December 16, 2022

Centering discussion on a patient scenario of stage II HR+ breast cancer, expert panelists consider how they would approach workup and selection of therapy.

August 12, 2021

Neil Iyengar, MD; Claudine Isaacs, MD; Virginia Kaklamani, MD; and Vijayakrishna Gadi, MD, PhD, share clinical pearls for the evolving treatment landscape of HER+ metastatic breast cancer.